Michael is a highly experienced successful pharmaceutical industry veteran. He has deep disease-specific and RNA therapeutics technical expertise. He is currently supporting a number of Biotechnology companies in the role of drug development consultant, non-executive director and/or scientific advisor. He is a member of the science advisory boards of Arcturus Therapeutics, Exicure Therapeutics and eFFECTOR Therapeutics and a scientific advisor for Adjuvant Capital.
He was previously the CMO of Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Prior to Amplyx he was the CMO for Santaris A/S, developing drug treatments for chronic viral diseases, cancer, metabolic/lipid and eye diseases. The company was acquired by Hoffman-La Roche, AG.
Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs where approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin).
He was a Non-Executive Director of F2G, an infectious disease biotechnology company from 2010-2014.
Dr. Hodges earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.